Related references
Note: Only part of the references are listed.Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials
Lei Wang et al.
CANCER SCIENCE (2019)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation
Hui Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo [4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer
Qihua Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
Wei Qiu et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2014)
Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors
Qihua Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
Andreina Peralta-Leal et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Inhibition of poly(ADP-ribose) pollyrnerase in cancer
Elizabeth Ruth Plummer
CURRENT OPINION IN PHARMACOLOGY (2006)
Share Paper
